3SBio Inc. (HKG: 1530) announced NMPA marketing approval for its generic version of Novartis’ Revolade (eltrombopag olamine), an oral thrombopoietin receptor agonist (TPO-RA) for chronic immune thrombocytopenia (ITP) and severe aplastic anemia (SAA). The approval adds 3SBio to a crowded field of Chinese eltrombopag copycats, including Qilu Pharmaceutical, Kelun Pharmaceutical, and Chia Tai Tianqing, intensifying price competition in the growing thrombocytopenia market as the originator’s China exclusivity (market entry 2017) expires.
Pediatric ITP (≥6 years) and SAA marketing; real-world evidence generation
Global Potential
2027+
Emerging market export; WHO prequalification for ITP/SAA
Forward‑Looking Statements This brief contains forward‑looking statements regarding pricing dynamics, market share capture, and competitive positioning for 3SBio’s eltrombopag generic. Actual results may differ due to volume-based procurement outcomes, physician prescribing patterns, and originator defense strategies.-Fineline Info & Tech
Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.
